Asthma and rhinoconjunctivitis comorbidity: United airway disease or inherited target organs?
Garcia-Marcos L, Ruiz TR, Garcia-Hernandez G, Suarez-Varela MM, Valverde-Molina J, Sanchez-Solis M. Asthma and rhinoconjunctivitis comorbidity: United airway disease or inherited target organs? Pediatr Allergy Immunol 2010: 21: e142–e148. © 2009 The Authors Journal compilation © 2009 Blackwell Munksgaard The idea of a united airway disease for asthma and rhinoconjunctivitis is supported by clinical and epidemiological data. However, many asthmatics do not have rhinoconjunctivitis and vice versa. The aim of this study was to investigate if the family history of a specific organ involvement is associated with the implication of the same organ in the allergic child. According to the organ invo…
The Nutrition in Early Life and Asthma (NELA) birth cohort study: Rationale, design, and methods.
Background Primary prevention strategies for asthma are lacking. Its inception probably starts in utero and/or during the early postnatal period as the developmental origins of health and disease (DOHaD) paradigm suggests. Objectives The main objective of Nutrition in Early Life and Asthma (NELA) cohort study is to unravel whether the following factors contribute causally to the developmental origins of asthma: (1) maternal obesity/adiposity and foetal growth; (2) maternal and child nutrition; (3) outdoor air pollution; (4) endocrine disruptors; and (5) maternal psychological stress. Maternal and offspring biological samples are used to assess changes in offspring microbiome, immune system,…
Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: Incidence and results of the national CF-COVID19-Spain survey
CF-COVID19-Spain Registry Group.
Cystic fibrosis treatment: targeting the basic defect
ABSTRACTIntroduction: Cystic Fibrosis (CF) is a disease caused by different class mutations in the CF transmembrane conductance regulator (CFTR) gene. It can therefore benefit from a personalized medicine approach based on the individual genotype of each patient.Areas covered: This review provides a detailed overview of the current major development of new CF treatments that target the basic CF defect. The review summarizes gene therapy, mRNA repair strategies, read-through agents, and CFTR-modulators (potentiators, correctors, stabilizers, amplifiers and different combination therapies).Expert opinion: We are currently perhaps at the most exciting stage in the history of CF, with the poten…